AQR Capital Management LLC cut its position in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 13.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,729 shares of the company’s stock after selling 14,253 shares during the period. AQR Capital Management LLC owned about 0.20% of Amphastar Pharmaceuticals worth $1,708,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in AMPH. BlackRock Fund Advisors increased its position in shares of Amphastar Pharmaceuticals by 105.3% in the third quarter. BlackRock Fund Advisors now owns 3,085,037 shares of the company’s stock worth $58,523,000 after buying an additional 1,581,978 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Amphastar Pharmaceuticals by 5.0% in the third quarter. Teachers Advisors LLC now owns 541,260 shares of the company’s stock worth $10,268,000 after buying an additional 25,700 shares during the last quarter. Kalmar Investments Inc. DE increased its position in shares of Amphastar Pharmaceuticals by 20.7% in the third quarter. Kalmar Investments Inc. DE now owns 254,418 shares of the company’s stock worth $4,826,000 after buying an additional 43,703 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth $5,829,000. Finally, Acadian Asset Management LLC raised its stake in shares of Amphastar Pharmaceuticals by 92.3% in the third quarter. Acadian Asset Management LLC now owns 1,573,986 shares of the company’s stock worth $29,858,000 after buying an additional 755,366 shares during the period. Hedge funds and other institutional investors own 49.09% of the company’s stock.
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) traded up 1.17% during midday trading on Thursday, hitting $14.68. 76,702 shares of the stock traded hands. The company’s 50 day moving average is $14.38 and its 200-day moving average is $17.33. Amphastar Pharmaceuticals Inc has a one year low of $11.41 and a one year high of $21.75. The company has a market cap of $673.96 million, a P/E ratio of 66.73 and a beta of 1.74.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Monday, March 13th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.02. Amphastar Pharmaceuticals had a net margin of 7.75% and a return on equity of 6.79%. The company earned $63.54 million during the quarter, compared to analysts’ expectations of $55.78 million. During the same period last year, the company posted $0.19 earnings per share. The business’s revenue for the quarter was down 17.4% on a year-over-year basis. On average, equities research analysts forecast that Amphastar Pharmaceuticals Inc will post $0.40 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/04/20/amphastar-pharmaceuticals-inc-amph-position-lowered-by-aqr-capital-management-llc-updated.html.
A number of brokerages have recently weighed in on AMPH. Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 17th. Jefferies Group LLC set a $21.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 14th. Raymond James Financial, Inc. lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and lowered their price target for the company from $21.00 to $18.00 in a report on Tuesday, March 14th. Piper Jaffray Companies lowered their price target on shares of Amphastar Pharmaceuticals from $22.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, March 14th. Finally, BMO Capital Markets lowered their price target on shares of Amphastar Pharmaceuticals from $18.00 to $16.00 and set a “market perform” rating on the stock in a report on Tuesday, March 14th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Amphastar Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $20.29.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.